Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants.
OBJECTIVE
To evaluate whether a prolonged low-dose course of indomethacin would produce an improved closure rate and have fewer side effects compared with a short standard dosage schedule in the management of patent ductus arteriosus (PDA) in preterm infants.


METHODS
Sixty-one infants of gestational ages 24 to 32 weeks with a PDA confirmed with echocardiography were randomized to receive 0.2 to 0.1 to 0.1 mg/kg indomethacin in 24 hours (short course, n = 31) or 0.1 mg/kg every 24 hours 7 times (long course, n = 30). Echocardiography was done 3, 9, and 14 days after the treatment was started, and side effects were monitored.


RESULTS
Primary PDA closure occurred more often in the short course group (94% vs 67%, P =.011), but the sustained closure rates were not different (74% vs 60%). Surgical PDA ligations were less frequent in the short course group than in the long course group. The short course group had a shorter duration of oxygen supplementation, less frequent symptoms of necrotizing enterocolitis, and a lower rate of urea retention. Mortality and other neonatal morbidity rates were similar.


CONCLUSIONS
A prolonged low-dosage indomethacin regimen offers no advantage compared with a standard-dosage short course in the management of a hemodynamically significant PDA in preterm infants.
Tammela
O
O
Departments of Paediatrics and Clinical Physiology, Tampere University Hospital, Tampere, Finland.
Ojala
R
R
Iivainen
T
T
Lautamatti
V
V
Pokela
M L
ML
Janas
M
M
Koivisto
M
M
Ikonen
S
S
D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D004374:Ductus Arteriosus, Patent / Q000175:diagnosis / Q000188:drug therapy*; D004452:Echocardiography; D005865:Gestational Age; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage* / Q000627:therapeutic use; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D016896:Treatment Outcome
D016861:Cyclooxygenase Inhibitors; D007213:Indomethacin